Attovia Therapeutics (ATTO) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($749.6 million vs $707.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | PRME |
|---|---|---|
| Share price | $16.42 | $3.90 |
| Market cap | $749.59M | $707.37M |
| 1-day change | -6.17% | +11.43% |
| YTD return | — | +12.39% |
| 1-year return | — | -33.56% |
| EPS (TTM) | $-2.56 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $6.65 |
| 52-week low | $16.15 | $2.67 |
| Distance from 52-week high | -41.36% | -41.35% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +157.00% | +82.31% |
| Average volume | 456.94K | 3.19M |
| Shares outstanding | 45.65M | 181.38M |
| Employees | 44 | 146 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Healthcare · Biotechnology · 44 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Healthcare · Biotechnology · 146 employees
ATTO vs PRME FAQ
Which is bigger, Attovia Therapeutics or Prime Medicine?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $749.59M compared with $707.37M for Prime Medicine (PRME).
Are Attovia Therapeutics and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.